대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	An Observational Study of Treatment on IgA Nephropathy with Telitacicept and Immunosuppressive Regimens in a Single Center
저자	Xuehong Lu
출판정보	2024; 2024(1):
키워드
초록	Objectives: To assess the safety and effectiveness of telitacicept when used in conjunction with immunosuppressive treatment plans for IgAN. Methods: 41 patients who met the inclusion criteria and had 24-hour proteinuria >0.5 g/d with IgAN were screened into two groups: the treatment group (n=20) and the control group (n=21). Both groups receive optimized supportive care for three months, during which time the treatment group receives a subcutaneous injection of 160 mg of telitacicept in addition to 0.5 mg/kg of methylprednisolone and/or mycophenolate mofetil, while the control group does not receive any telitacicept treatment for 24 weeks. The 24-hour proteinuria change at week 24 was the primary endpoint, and the change in eGFR was the secondary goal. Results: Week 24 saw a 58.66% (mean difference -2.27, 95% confidence interval, -0.72to-3.82, p=0.004) decrease in 24-hour proteinuria in the treatment group(Figure), and 22.92% (mean difference -1.93, 95% confidence interval, -2.68to-1.17, p<0.001) decrease in IgG, 44.61% (mean difference -1.20, 95% confidence interval, -1.70to-0.73, p<0.001) decrease in IgA, and 46.79% (mean difference -0.51, 95% confidence interval, -0.73to-0.29, p<0.001) decrease in IgM in the treatment group. The change in 24-hour proteinuria in the control group was observed to be 39.13% lower than the baseline at week 24 (mean difference -0.63, 95% confidence interval, -1.01 to -0.25, p=0.002) (Figure). Both before and after therapy, the eGFR in both groups stayed comparatively constant. Both groups experienced similar adverse events; no serious adverse events were reported. Conclusions: To a certain extent, telitacicept can slow the progression of IgAN by reducing the levels of 24-hour proteinuria, IgG, IgA, and IgM.
원문(PDF)	PDF 원문보기

목록

위로가기